Calendar
International Society for Experimental
Hematology Annual Scientific Meeting
August 22 – 25, 2019
Brisbane, Australia
The 48th Annual Scientific Meeting of the International
Society for Experimental Hematology blends educational
sessions on basic, translational, and clinical hematol-
ogy with unique networking opportunities for senior
scientists and new investigators.
17th International Myeloma Workshop
ASH Meeting on Hematologic Malignancies
Chicago, IL
September 6 – 7, 2019
Chicago, IL
Top experts in hematologic malignancies discuss the latest developments in clinical care and provide answers to
challenging patient care questions in a small-group setting. The program content is structured as “How I Treat”
presentations, which showcase each speaker’s evidence-based treatment approaches.
Efficacy in treatment-naïve patients (N=29) 1
72%
CR/CRc
rate*
90%
ORR
45%
bridged to stem cell
transplantation
* CRc = clinical complete response; defined as complete response with residual skin abnormality not indicative of active disease. 2
CR = complete response; ORR = overall response rate.
Median duration of CR/CRc has not yet been reached; median follow-up 19 months
(range, 1-42 months). 1
Median overall survival not yet reached; median follow-up 25 months. 1
In the pivotal cohort, treatment-naïve patients (N=13) achieved a 54% CR/CRc rate,
77% ORR, and 46% bridged to stem cell transplantation. 2,3
ELZONRIS TM (tagraxofusp-erzs) was evaluated in treatment-naïve and previously-treated patients with BPDCN in
an open-label, multicenter clinical study (N=44). The pivotal cohort consisted of 13 treatment-naïve patients. 1,2
VISIT ELZONRIS.COM/HCP FOR MORE INFORMATION.
Hypersensitivity Reactions ADVERSE REACTIONS:
• ELZONRIS can cause severe hypersensitivity reactions. Grade 3
or higher events were reported in 10% of patients in clinical
trials. Monitor patients for hypersensitivity reactions during
treatment with ELZONRIS. Interrupt ELZONRIS infusion and
provide supportive care as needed if a hypersensitivity
reaction should occur. If the reaction is severe, discontinue
ELZONRIS permanently
Hepatotoxicity
• Elevations in liver enzymes can occur with ELZONRIS.
Grade 3 or higher elevations in liver enzymes occurred
in approximately 40% of patients in clinical trials
• Monitor alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) prior to each infusion with ELZONRIS.
Temporarily withhold ELZONRIS if the transaminases rise to
greater than 5 times the upper limit of normal (ULN) and
resume treatment upon normalization or when resolved The most common adverse reactions in the clinical trials
(incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue,
peripheral edema, pyrexia, and weight increase. The most
common laboratory abnormalities (incidence ≥ 50%) are
decreases in albumin, platelets, hemoglobin, calcium,
sodium, and increases in glucose, ALT, and AST.
Please see Brief Summary of full Prescribing Information,
including Boxed WARNING, on the following pages.
To report SUSPECTED ADVERSE REACTIONS, contact Stemline
Therapeutics, Inc. at 1- 877-332-7961 or contact the FDA at
1- 800-FDA-1088 or www.fda.gov/medwatch.
References: 1. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic
plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628-1637.
2. ELZONRIS [prescribing information]. New York, NY, US: Stemline Therapeutics, Inc.;
December 2018. 3. Data on file. Stemline Therapeutics, Inc.
September 12 – 15, 2019
Boston, MA
The International Myeloma Society’s annual workshop
invites more than 3,000 participants to discuss the
latest genomic advances, new drugs, and new agents in
myeloma and related plasma cell disorders.